Dr. Sean Conley is the president's personal doctor. He said "though he may not be entirely out of the woods yet, the team and I agree that all our evaluations... support the president's safe return home."
肖恩·康利博士是总统的私人医生。他说：“虽然他可能还没有完全康复，但我和我的团队都同意，我们所有的评估都支持总统安全回家。”
Conley added that privacy "rules and regulations" bar him from sharing information to protect Trump's safety and health.
康利还表示，隐私“规章制度”禁止他分享信息以保护川普的安全和健康。
Trump announced last Friday that he and his wife Melania had tested positive for COVID-19. He has since received several aggressive treatments for the coronavirus during a three-day stay at Walter Reed medical center.
川普上周五宣布，他和妻子梅拉尼娅的新冠肺炎检测呈阳性。此后他在沃尔特·里德医疗中心住了三天，并接受了多种新冠病毒的积极治疗。
Oxygen treatment
吸氧治疗
Dr. Conley first said on Friday that the president "was doing well with only mild symptoms."
康利博士周五最初表示，总统“状况良好，仅有轻微症状。”
Conley later said Trump got "high fever," or high body temperature, and was given oxygen. He said the president's blood oxygen level was below 94 percent.
后来康利说川普发烧了，并且吸了氧。他说川普的血氧浓度低于94%。
The National Institutes of Health's COVID-19 treatment guidelines consider those with blood oxygen level at 94 percent or lower as having moderate to severe illness. The health agency notes that a low level of blood oxygen is common among COVID-19 patients.
美国国立卫生研究院发布的新冠肺炎治疗指南认为血氧浓度不超过94%是中重度患者。这家卫生机构表示，血氧浓度低在新冠肺炎患者中很常见。
Regeneron's antibody treatment
再生元公司的抗体治疗
As the president was transported Friday to Walter Reed Medical Center, Conley released a letter saying that the president received an 8-gram dose of experimental antibody treatment from the company Regeneron Pharmaceuticals, Inc. The president also took substances such as: "zinc, vitamin D, famotidine, melatonin and a daily aspirin."
当川普总统周五被送到沃尔特·里德医疗中心时，康利发表了一封信，称川普接受了再生元公司8克剂量的实验性抗体疗法。川普总统还服用了诸如“锌、维生素D、法莫替丁、褪黑素和阿司匹林。”
Regeneron's antibody treatment, called REGN-COV2, started its human trial in late June. It combines a "genetically-modified" antibody made by the company and a second antibody from recovered COVID-19 patients.
再生元公司这种被称为REGN-COV2的抗体疗法已于6月下旬进入人体试验阶段。它结合了该公司生产的“经过基因编辑的”抗体以及来自新冠肺炎患者的第二种抗体。
The treatment is designed to connect the antibodies to the virus that causes COVID-19 and limit its ability to spread in an infected person. This idea has been used in the past to develop drugs to treat other viruses such as HIV, the cause of the disease AIDS.
这种疗法的设计目的是将抗体与引发新冠肺炎的病毒结合，并限制其在感染者体内的传播能力。这种理念过去已经被用于开发药物治疗其它病毒，例如引发艾滋病的艾滋病毒。
On September 29, the New York-based company told investors that the treatment appeared to be safe. The company said in a statement that the treatment also reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients.
9月29日，这家位于纽约的公司对投资者表示，这种疗法似乎是安全的。该公司在一份声明中表示，这种疗法降低了非住院新冠肺炎患者的病毒水平并改善了症状。
The treatment, however, has not been studied by independent scientists. And it has not been approved for emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA).
然而这种疗法尚未经过独立科学家的研究。而且它也尚未获得美国食品药品监督管理局紧急使用授权的批准。
Remdesivir
瑞德西韦
During a news conference Saturday, the president's doctors confirmed that he has started a five-day treatment of the anti-viral drug remdesivir on Friday.
在周六的新闻发布会上，总统的医生证实，他已于周五开始接受抗病毒药物瑞德西韦为期5天的治疗。
The FDA first approved remdesivir for the treatment of hospitalized patients "with severe COVID-19" in May. The agency expanded the emergency use authorization in August to anyone with COVID-19, regardless of the severity of their disease.
美国食品药品监督管理局于5月份首次批准了瑞德西韦用于治疗新冠肺炎重症住院患者。该机构在8月份将紧急使用授权扩大到所有新冠肺炎患者，而不管其严重程度。
The drug appeared to help patients with moderate COVID-19 to recover faster after a five-day treatment when compared to others with usual care. The result was published in the Journal of the American Medical Association in August.
与其它常规治疗药物相比，该药物似乎可以在5天的治疗后帮助中度新冠肺炎患者更快恢复。这一研究结果于8月份发表在《美国医学会期刊》上。
The National Institutes of Health (NIH) says the drug "works by stopping the virus from spreading in the body." The health agencies warned of possible side effects including damage to liver, low blood pressure and vomiting.
美国国立卫生研究院表示，该药物“通过阻断病毒在体内传播而起效。”该卫生机构也警告了其潜在副作用，包括损伤肝脏、降低血压以及呕吐。
Dexamethasone
地塞米松
On Sunday, Dr. Conley reported that Trump's blood oxygen level on Saturday "dropped down to about 93 percent." He added, "We watched it and it returned back up."
周六，康利博士报告称川普的血氧浓度当天“降至约93%。”他还表示：“我们看着它没管，然后它又恢复了。”
The president's doctor also said Trump was given another drug, dexamethasone.
这位总统医生还表示，川普还服用了另一种药物地塞米松。
Last June, researchers at the University of Oxford found that dexamethasone cut death rates by around a third among patients with the most severe cases of COVID-19. The drug has been in use since the 1960s to reduce swelling caused by diseases such as arthritis. The researchers said the findings suggest doctors should use the drug immediately as usual treatment for severely sick patients.
去年6月，牛津大学的研究人员发现，地塞米松使最严重的新冠肺炎患者的死亡率降低了约1/3。自上世纪60年代以来，该药物一直被用于减少由关节炎之类的疾病引发的肿胀。研究人员表示，该研究结果表明，医生应该立即将这种药物作为重症患者的常规治疗方法来使用。
The World Health Organization's Director-General Tedros Adhanom Ghebreyesus said at the time, "This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support."
世卫组织总干事谭德塞当时表示：“这是第一种被证实可以降低需要氧气或呼吸机支持的新冠肺炎患者的死亡率的治疗方法。”
The NIH advises that the drug be used only for hospitalized COVID-19 patients who require oxygen or ventilator support. The guidelines suggest 6 mg a day for up to 10 days or until leaving the hospital.
美国国立卫生研究院建议该药物仅用于需要氧气或呼吸机支持的新冠肺炎住院患者。这份指南建议每天服用6毫克，持续10天或直到出院为止。
The agency says the drug has no benefit for patients who do not need oxygen help. And it could limit the body's ability to fight against infection.
该机构表示，这种药物对无需氧气支持的患者没有好处。它还可能会限制人体抵抗感染的能力。
The coronavirus has now infected more than 35 million people around the world. Johns Hopkins University's Coronavirus Center reported that the disease has also killed more than 1 million people, including about 210,000 in the U.S.
新冠肺炎已经导致全球3500万人感染。约翰·霍普金斯大学的新冠病毒资源中心报告称，这种病毒还导致了超过100万人死亡，其中包括美国死亡的21万人。